SOPHiA GENETICS, a leader in cloud-native healthcare technology, has announced an expanded partnership with Result Laboratorium in the Netherlands to enhance the delivery of pharmacogenomics insights using the SOPHiA DDM™ Platform. This collaboration aims to make pharmacogenomics more accessible across the region by leveraging scalable, decentralized genomics. The SOPHiA DDM™ Platform is GDPR and HIPAA compliant, ensuring high standards of data security and privacy. By acting as a regional hub, Result Laboratorium will enable other institutions to scale pharmacogenomics analysis without needing to develop complex infrastructure, thereby supporting more personalized care through a secure and scalable data ecosystem.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。